Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Privi Speciality Chemicals Ltd

| Audited Standalone Statement of Assets and Liabilities as at March 31, 2026

Report Source

⬤11th May 26

Summary : Privi Speciality Chemicals reported strong FY26 financial results, with significant profit growth and a recommended dividend, receiving an unmodified audit opinion.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Cost of materials consumed (Standalone FY26): 1,25,787.35 Lakhs.
  2. Employee benefits expense (Standalone FY26): 9,507.76 Lakhs.
  3. Finance costs (Standalone FY26): 6,683.82 Lakhs.
  4. Depreciation and amortisation expense (Standalone FY26): 13,020.93 Lakhs.
  5. Power and fuel expense (Standalone FY26): 16,802.80 Lakhs.
  6. Other expenses (Standalone FY26): 29,334.52 Lakhs.
  7. Standalone Revenue from Operations (FY26): 2,45,553.47 Lakhs.
  8. Consolidated Revenue from Operations (FY26): 2,56,368.55 Lakhs.
  9. Other income (Standalone FY26): 1,688.39 Lakhs.
  10. Other income (Consolidated FY26): 1,923.55 Lakhs.
  11. Cash flow from operating activities (Standalone FY26): 55,927.97 Lakhs.
  12. Net cash used in investing activities (Standalone FY26): (35,414.47) Lakhs.
  13. Net cash used in financing activities (Standalone FY26): (21,172.69) Lakhs.
  14. Cash flow from operating activities (Consolidated FY26): 55,008.69 Lakhs.
  15. Net cash used in investing activities (Consolidated FY26): (35,808.18) Lakhs.
  16. Net cash used in financing activities (Consolidated FY26): (19,767.01) Lakhs.
  17. Total Assets (Standalone FY26): 2,88,309.87 Lakhs (vs 2,47,343.61 Lakhs in FY25).
  18. Total Equity (Standalone FY26): 1,43,764.15 Lakhs (vs 1,10,119.27 Lakhs in FY25).
  19. Total Assets (Consolidated FY26): 3,16,982.01 Lakhs (vs 2,79,050.62 Lakhs in FY25).
  20. Total Equity (Consolidated FY26): 1,44,060.91 Lakhs (vs 1,11,792.13 Lakhs in FY25).
  21. Capital work-in-progress (Standalone FY26): 21,740.42 Lakhs (vs 5,628.57 Lakhs in FY25).
  22. Capital work-in-progress (Consolidated FY26): 29,764.82 Lakhs (vs 12,747.22 Lakhs in FY25).
  23. Mr. Bhaktavatsala Rao Doppalapudi is not related to any other Director of the Company.
  24. Both standalone and consolidated financial results are provided and audited.

Corporate Overview

  1. Presence in USA through subsidiary Privi Speciality Chemicals USA Corporation.
  2. Manufacture and sale of Aroma Chemicals.
  3. Factual and compliant, reporting strong financial performance and key board decisions.
  4. Single segment: Aroma Chemical.
  5. Significant capital work-in-progress increase (Standalone: 21,740.42 Lakhs in 2026 from 5,628.57 Lakhs in 2025; Consolidated: 29,764.82 Lakhs in 2026 from 12,747.22 Lakhs in 2025).

Risk Factors

  1. No specific risks identified in this report.
  2. Report does not detail explicit risk factors.
  3. Company operates in a single business segment.
  4. Future reports may disclose detailed risk factors.

Key Drivers

  1. Strong financial performance, increased profits.
  2. Recommended final dividend of Rs. 10.
  3. Unmodified audit opinion received for financials.
  4. Key Executive Director re-appointed.

Auditor’s Report

  1. Unmodified opinion on standalone and consolidated financial results for the year ended March 31, 2026.

Board Commentary

  1. Re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for three years (August 13, 2026 to August 12, 2029).
  2. Re-appointment of M/s. Aneja Associates as Internal Auditor for FY 2026-27.
  3. Re-appointment of M/s Kishore Bhatia & Associates as Cost Auditors for FY 2026-27.
  4. Recommended final dividend of Rs. 10/- (100%) per equity share for FY 2025-26, subject to shareholder approval.
  5. Significant increase in capital work-in-progress, indicating ongoing projects and investments.

Corporate Governance

  1. Executive Director Mr. Bhaktavatsala Rao Doppalapudi is not related to any other Director.